吡非尼酮治疗慢性过敏性肺炎：真实病例经验
Pirfenidone in chronic hypersensitivity pneumonitis: a real-life experience.
作者信息
Shibata Sho, Furusawa Haruhiko, Inase Naohiko
机构信息
Department of Respiratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
出版信息
Sarcoidosis Vasc Diffuse Lung Dis. 2018;35(2):139-142. doi: 10.36141/svdld.v35i2.6170. Epub 2018 Apr 28.
Abstract
Pirfenidone is an antifibrotic drug used for the treatment of idiopathic pulmonary fibrosis. The aim of this study was to evaluate the efficacy of pirfenidone in patients with chronic hypersensitivity pneumonitis (HP). Twenty-three patients with chronic HP treated with pirfenidone were enrolled in this study based on a retrospective medical record review. The change in vital capacity (VC) in the 6 months after the start of treatment (-152±56.1 ml) was significantly improved compared with that in the 6 months before treatment (-292±77.8 ml, p=0.047). No patients discontinued the treatment with adverse events. These results demonstrate that pirfenidone may reduce the decline of VC in patients with chronic HP without eliciting significant adverse events. .
摘要
吡非尼酮是一种用于治疗特发性肺纤维化的抗纤维化药物。本研究的目的是评估吡非尼酮对慢性过敏性肺炎（HP）患者的疗效。基于回顾性病历审查，23例接受吡非尼酮治疗的慢性HP患者被纳入本研究。治疗开始后6个月时的肺活量（VC）变化（-152±56.1 ml）与治疗前6个月相比（-292±77.8 ml，p = 0.047）有显著改善。没有患者因不良事件而停止治疗。这些结果表明，吡非尼酮可能会减少慢性HP患者VC的下降，且不会引发明显的不良事件。
相似文献
1
Pirfenidone in chronic hypersensitivity pneumonitis: a real-life experience.吡非尼酮治疗慢性过敏性肺炎：真实病例经验
Sarcoidosis Vasc Diffuse Lung Dis. 2018;35(2):139-142. doi: 10.36141/svdld.v35i2.6170. Epub 2018 Apr 28.
2
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases.吡非尼酮治疗特发性肺纤维化：来自德国间质性肺疾病三级转诊中心的真实病例经验
Respiration. 2014;88(3):199-207. doi: 10.1159/000363064. Epub 2014 Aug 9.
3
Composite Physiologic Index, Percent Forced Vital Capacity and Percent Diffusing Capacity for Carbon Monoxide Could Be Predictors of Pirfenidone Tolerability in Patients with Idiopathic Pulmonary Fibrosis.综合生理指数、用力肺活量百分比和一氧化碳弥散量百分比可能是特发性肺纤维化患者吡非尼酮耐受性的预测指标。
Intern Med. 2015;54(22):2835-41. doi: 10.2169/internalmedicine.54.4118. Epub 2015 Nov 15.
4
Predictive factors for the effect of pirfenidone in idiopathic pulmonary fibrosis.吡非尼酮治疗特发性肺纤维化疗效的预测因素。
Sarcoidosis Vasc Diffuse Lung Dis. 2017;34(4):290-299. doi: 10.36141/svdld.v34i4.5630. Epub 2017 Apr 28.
5
Periostin as a predictor of prognosis in chronic bird-related hypersensitivity pneumonitis.骨膜蛋白作为慢性鸟相关过敏性肺炎预后的预测因子。
Allergol Int. 2019 Jul;68(3):363-369. doi: 10.1016/j.alit.2019.02.007. Epub 2019 Mar 11.
6
Difference in the phenotypes of bronchoalveolar lavage lymphocytes in patients with summer-type hypersensitivity pneumonitis, farmer's lung, ventilation pneumonitis, and bird fancier's lung: report of a nationwide epidemiologic study in Japan.夏季型过敏性肺炎、农民肺、通风性肺炎和养鸟人肺患者支气管肺泡灌洗淋巴细胞表型的差异：日本一项全国性流行病学研究报告
J Allergy Clin Immunol. 1991 May;87(5):1002-9. doi: 10.1016/0091-6749(91)90423-l.
7
Clinical experience with antifibrotics in fibrotic hypersensitivity pneumonitis: a 3-year real-life observational study.抗纤维化药物治疗纤维化性过敏性肺炎的临床经验：一项为期3年的真实世界观察性研究。
ERJ Open Res. 2020 Nov 2;6(4). doi: 10.1183/23120541.00152-2020. eCollection 2020 Oct.
8
Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan.吡非尼酮的疗效与特发性肺纤维化的疾病严重程度：日本III期试验的扩展分析
Respir Investig. 2015 Nov;53(6):279-87. doi: 10.1016/j.resinv.2015.06.002. Epub 2015 Oct 23.
9
Design and rationale of a randomised, double-blind trial of the efficacy and safety of pirfenidone in patients with fibrotic hypersensitivity pneumonitis.吡非尼酮治疗纤维化性过敏性肺炎患者疗效及安全性的随机双盲试验设计与原理
ERJ Open Res. 2021 Jun 7;7(2). doi: 10.1183/23120541.00054-2021. eCollection 2021 Apr.
10
Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.乙酰半胱氨酸和吡非尼酮联合治疗特发性肺纤维化的安全性和耐受性：一项随机、双盲、安慰剂对照、2 期临床试验。
Lancet Respir Med. 2016 Jun;4(6):445-53. doi: 10.1016/S2213-2600(16)30044-3. Epub 2016 May 5.
引用本文的文献
1
Diagnosis and Treatment of Hypersensitivity Pneumonitis: S2k Guideline of the German Respiratory Society and the German Society for Allergology and Clinical Immunology.过敏性肺炎的诊断与治疗：德国呼吸学会和德国变态反应与临床免疫学会S2k指南
Respiration. 2025;104(7):485-528. doi: 10.1159/000543675. Epub 2025 Jan 27.
2
Hypersensitivity Pneumonitis: Challenges of a Complex Disease.过敏性肺炎：一种复杂疾病的挑战。
Can Respir J. 2024 Jan 18;2024:4919951. doi: 10.1155/2024/4919951. eCollection 2024.
3
Criteria for progressive fibrotic hypersensitivity pneumonitis in a Portuguese patient cohort.葡萄牙患者队列中进行性纤维化性过敏性肺炎的标准
Afr J Thorac Crit Care Med. 2022 Dec 19;28(4). doi: 10.7196/AJTCCM.2022.v28i4.250. eCollection 2022.
4
Dyskeratosis congenita with heterozygous mutations presenting with fibrotic hypersensitivity pneumonitis.伴有杂合突变的先天性角化不良伴纤维化性过敏性肺炎。
Respir Med Case Rep. 2023 Jan 5;42:101810. doi: 10.1016/j.rmcr.2023.101810. eCollection 2023.
5
Diagnosis, course and management of hypersensitivity pneumonitis.过敏性肺炎的诊断、病程和管理。
Eur Respir Rev. 2022 Feb 9;31(163). doi: 10.1183/16000617.0169-2021. Print 2022 Mar 31.
6
Addition of antifibrotic therapy to immunosuppression in hypersensitivity pneumonitis: A case series.在过敏性肺炎中，在免疫抑制基础上加用抗纤维化治疗：病例系列
Respir Med Case Rep. 2021 Dec 2;34:101562. doi: 10.1016/j.rmcr.2021.101562. eCollection 2021.
7
Hypersensitivity Pneumonitis: Diagnostic and Therapeutic Challenges.过敏性肺炎：诊断与治疗挑战
Front Med (Lausanne). 2021 Sep 23;8:718299. doi: 10.3389/fmed.2021.718299. eCollection 2021.
8
A Review of Pirfenidone as an Anti-Fibrotic in Idiopathic Pulmonary Fibrosis and Its Probable Role in Other Diseases.吡非尼酮作为特发性肺纤维化抗纤维化药物的综述及其在其他疾病中的潜在作用
Cureus. 2021 Jan 4;13(1):e12482. doi: 10.7759/cureus.12482.
9
Cytokine gene polymorphisms in Pigeon Breeder's Disease expression.鸽禽饲养员病表达中的细胞因子基因多态性。
Sarcoidosis Vasc Diffuse Lung Dis. 2020;37(3):e2020004. doi: 10.36141/svdld.v37i3.9342. Epub 2020 Sep 30.
10
Clinical experience with antifibrotics in fibrotic hypersensitivity pneumonitis: a 3-year real-life observational study.抗纤维化药物治疗纤维化性过敏性肺炎的临床经验：一项为期3年的真实世界观察性研究。
ERJ Open Res. 2020 Nov 2;6(4). doi: 10.1183/23120541.00152-2020. eCollection 2020 Oct.
本文引用的文献
1
Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis.吡非尼酮治疗与无肌病性皮肌炎相关的快速进展性间质性肺病患者。
Sci Rep. 2016 Sep 12;6:33226. doi: 10.1038/srep33226.
2
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.美国胸科学会/欧洲呼吸学会/日本呼吸学会/拉丁美洲胸科学会特发性肺纤维化临床实践指南：治疗。对 2011 年临床实践指南的更新。
Am J Respir Crit Care Med. 2015 Jul 15;192(2):e3-19. doi: 10.1164/rccm.201506-1063ST.
3
Fibrocytes contribute to inflammation and fibrosis in chronic hypersensitivity pneumonitis through paracrine effects.成纤维细胞通过旁分泌作用促进慢性变应性肺炎的炎症和纤维化。
Am J Respir Crit Care Med. 2015 Feb 15;191(4):427-36. doi: 10.1164/rccm.201407-1334OC.
4
Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease.吡非尼酮治疗五例硬皮病相关间质性肺病的临床经验。
Sarcoidosis Vasc Diffuse Lung Dis. 2014 Oct 20;31(3):235-8.
5
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.吡非尼酮治疗特发性肺纤维化患者的 3 期临床试验。
N Engl J Med. 2014 May 29;370(22):2083-92. doi: 10.1056/NEJMoa1402582. Epub 2014 May 18.
6
Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.过敏性肺炎：诊断与病理生物学的新认识。
Am J Respir Crit Care Med. 2012 Aug 15;186(4):314-24. doi: 10.1164/rccm.201203-0513CI. Epub 2012 Jun 7.
7
Pirfenidone in idiopathic pulmonary fibrosis.吡非尼酮治疗特发性肺纤维化。
Eur Respir J. 2010 Apr;35(4):821-9. doi: 10.1183/09031936.00005209. Epub 2009 Dec 8.
8
Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis.吡非尼酮和泼尼松龙的抗纤维化作用：对博来霉素诱导的小鼠肺纤维化中肺细胞因子和生长因子的不同影响
Eur J Pharmacol. 2008 Aug 20;590(1-3):400-8. doi: 10.1016/j.ejphar.2008.06.046. Epub 2008 Jun 16.
9
Chronic hypersensitivity pneumonitis.慢性过敏性肺炎
Am J Surg Pathol. 2006 Feb;30(2):201-8. doi: 10.1097/01.pas.0000184806.38037.3c.
10
Chronic hypersensitivity pneumonitis in Japan: a nationwide epidemiologic survey.日本慢性过敏性肺炎：一项全国性流行病学调查。
J Allergy Clin Immunol. 1999 Feb;103(2 Pt 1):315-20. doi: 10.1016/s0091-6749(99)70507-5.
Zotero 插件